Thanks for joining. We are with Ahmed Mousa, CEO of Vicore Pharma. Thanks for taking the time and being with us. Maybe for those who are less familiar with the company, could you maybe give a quick introduction to the product, what you are doing in IPF?
Yeah, absolutely. Thanks for having us, Clémence, and thanks to the Stifel team for inviting us to your conference again. Vicore Pharma is a company that has been really focused on the biology and chemistry of the angiotensin II pathway. In particular, we have zeroed in on a receptor known as the angiotensin II type 2 receptor, which drives an endogenous tissue repair and fibrosis resolution system. What we have built at Vicore is the ability to modulate and characterize modulation of that pathway, and really see how we can drive that mechanism of action against a number of fibrotic and inflammatory diseases.
For our lead compound and our lead indication, we have really focused in on quite a tough disease called idiopathic pulmonary fibrosis. We have produced some very nice preclinical translational data showing that we can have a strong effect there, some nice data in phase I showing that our lead candidate, buloxibutid, has good safety tolerability profile. Then in our phase IIa study, a nine-month study, we actually showed a nice signal of clinical activity in pulmonary fibrosis. Now what we are doing and what we have ongoing is a large phase IIb trial to really confirm that signal and set us on the path to hopefully phase III and ultimately commercialization of the therapy.
In your phase II study, in IPF, we are looking to slow the decline lung function. What you showed was actually improvement, which is quite striking. Can you walk us through the result of that study and kind of what gives you confidence that it can be reproduced in a phase III?
Yeah, absolutely. What we did in our clinical program to date is really look in the phase IIa study at our therapy, buloxibutid, in treatment-naive IPF patients, IPF patients who had not yet taken any therapy, and we treated them in monotherapy over a nine-month period. As you say, what we observed over that nine-month period is not just a slowing of the decline of lung function, but rather the ability to ultimately improve lung function in the observed dataset in these IPF patients. I think that's a very exciting signal of clinical activity. I think what we do have to recognize is the study was relatively small. It was open label, so there wasn't a placebo arm. I think that part of the role of the ongoing phase IIb then is to determine the exact effect size.
I think the really important thing to highlight is, this disease, IPF, is very tough. It's unfortunately a disease where the prognosis is only three- to five-year survival, so it's actually worse than many cancers. Even though this is such a deadly disease, most patients in the U.S., and this is similar in Europe and other countries as well, who are diagnosed with IPF don't even initiate the currently available therapies, the standard of care therapies. There are three that are currently available. That's because they both have a very incremental effect on lung function. Ultimately, they don't significantly change that survival picture. In addition to that, they have a very tough tolerability profile.
In particular, the three that are approved cause significant gastrointestinal side effects, nausea, vomiting, diarrhea. There is a really high need for much better tolerated therapies, which we think buloxibutid is based on all the data we've generated to date. Then certainly, if you can show efficacy at those levels or above, it's a very attractive therapy and one that I think that patients would be excited to take. From that perspective, we're really excited about this initial signal and very excited to have finished completion of enrollment of our phase IIb and planning for a readout in the middle of next year.
Okay. If we look at the details of the phase IIa, sorry, the patient, you also looked at fibrosis-related biomarkers. Were you able to identify patients that were likely to respond, or if there was a correlation between those biomarkers and the improvement you saw?
Yeah. IPF is tough because the measurement, the approval endpoint measurement, which is called FVC or forced vital capacity, it's a measurement of lung function, has actually a bit of variability associated with it. Because essentially, what you're asking is for these IPF patients to breathe in as hard as they can so you can measure their total lung capacity. There's naturally variability associated with that. That's part of the reason why clinical trials in IPF need to be relatively large and relatively lengthy in order for you to really be able to detect signals of clinical activity. What I can say we saw in the phase IIa is some really nice biomarker evidence that we're producing the effect that we think this mechanism shows.
I'll give you kind of one example, which is a collagenase matrix metalloproteinase, MMP13, which is responsible for essentially digesting existing fibrotic matrix. We think that the upregulation of that enzyme across the 36-week phase IIa IPF study, and we saw this in the blood of the IPF patients that were in our trial, is a really nice signal that also then matches with that signal, the clinical signal of activity on the forced vital capacity that we mentioned. Nice to see that the mechanism is working and that you see the corresponding clinical effect as well. I think that you don't always see it kind of one-to-one in the exact same way in the exact same patient, but that's not necessarily surprising at all.
I think one of the other really nice things to see in our phase IIa dataset is that we have an effect in a broad range of patients, like different status in terms of percent predicted FVC at baseline. We had a nice effect in both men and women who enrolled in our trial. We also had an effect in both the patients with what's called probable UIP and typical UIP. These are basically high-resolution CT scan patterns, and they basically reflect earlier stage disease and later stage disease. To be able to show that we can stabilize or maybe even improve lung function in both of those types of populations is really attractive.
I think finally, we ran the study in a couple of geographies, but we enrolled a lot of patients out of the U.K. and India in particular, and to see that also in both of those sub-geographies, you also see this signal of improvement or stabilization in lung function at 52 weeks, sorry, at 36 weeks, both at mean and at median. I think what that's also reflective of is, in some IPF datasets in the past, we've seen kind of results that look like the compound is very active, but it's driven by one or two outliers. We don't have that in our phase IIa signal. What we have is 65% of the patients at 36 weeks have improvement in lung function, and 80% have a better lung function than what you'd expect relative to patients who would otherwise be untreated over that 36-week period.
Hmm. That's a nice coverage of the heterogeneity. We'll come back to also the baseline characteristic of your phase IIb. Just on the tolerability, as you said, drugs available are quite toxic, poorly tolerated. There are patients that don't initiate, but there's also quite a lot of discontinuation once they get in treatment. Is there anything that you're particularly monitoring in your trial based on what you've seen or what you know about the mechanism of action of buloxibutid?
In the ongoing phase IIb?
Yeah.
Or, yeah.
Based on what you saw on the phase IIa.
Got it. Yes. I mean, certainly, again, and this is part and parcel of, unfortunately, the bar in IPF being so low because the standard of care therapies have the challenges that we've talked about. What is both kind of necessary and sufficient for approval of a new therapy in IPF is a clinically meaningful impact on FVC, right? We've seen therapies become approved for IPF where actually they show a good result on FVC, even if they show kind of no significant result on any other endpoint. Certainly, the ultimate focus here is on preserving lung function or significantly slowing the decline of lung function, or hopefully even maybe replicating some improvement in the population.
In addition to that, of course, we do want to positively impact other features. Certainly, we're going to look at a number of other parameters. One thing that we'll look at in our phase IIb is the lung characteristics based on the imaging, so high-resolution CT scans at the beginning and the end of the trial, so we can see how those kind of features are changing alongside the lung function, the FVC. In addition to that, of course, we'll continue to look at biomarkers to see if we have that same kind of signal and evidence that we're able to impact the disease through the mechanism as we understand it.
In addition to that, and very importantly, we'll look at some of the quality of life metrics. I think that that's both a reflection that hopefully you're having clinical benefit for patients, but also that maybe your tolerability profile is good because patients are able to take it and feel like they're doing better as well. I think that, generally speaking, I think those are the types of endpoints that we're looking forward to looking at as we unblind the results next year of the phase IIb trial, and certainly to report on publicly as well.
Okay. And just to conclude on the phase IIa, it was a single-arm study, but you've used that sort of synthetic control arm to try to put the result into context. What have you seen looking at that control?
Yeah, absolutely. We conducted an exercise where we leveraged a relatively large dataset of real-world IPF patients. Then we took this dataset, and we narrowed it to the group of IPF patients who would have been eligible to enroll in our phase IIa. So had the baseline lung characteristics, they had the other features that would be considered relevant for inclusion and exclusion. Then in that narrower dataset, we then did some matching. Essentially, ultimately looked at those patients who most closely matched the actual patients that we enrolled in our phase IIa trial, based on a number of features, of course, in particular, like the lung function at baseline being some of the key characteristics, including FVC, FEV1, and other features as well.
When you take those patients that most closely look like who we enrolled in the phase IIa from that real-world dataset. What you see is that over a 36-week period, they have a decline in lung function of about 115 ml. I think that's a nice confirmation that the patients who came into our phase IIa trial would be expected to have a decline in lung function, and so it was actually quite unexpected to see the clinical signal that we did in the phase IIa, absent a therapeutic activity of buloxibutid in that setting. One of the challenges of the phase IIa is there were some discontinuation, and discontinuation is part of the reality of all IPF trials.
Unfortunately, because it's a fatal disease, because it's a patient population with lots of comorbidities, there is always discontinuation in these types of trials. One thing that we also wanted to look at is then saying, okay, when we talk about the improvement in lung function of 200 ml at 36 weeks, that's in the observed dataset, but we also then did a very conservative imputation analysis using the synthetic control arm data, and we said, "Let's actually assume then that every patient as they discontinued would have a placebo-like decline, that 115 ml over 36-week trajectory."
If you impute the dataset in that conservative way, you still actually have a significant difference between that synthetic placebo decline at 36 weeks, - 115 ml, and + 20 ml effect in the kind of now imputed treatment arm, which would give you like 135 ml delta. It is nice to see that even when you look at the dataset with a very conservative lens, you still see this nice clinical effect. I think that was very motivating for us in moving forward, and we are really excited on that basis to see what the drug does in this larger phase IIb trial.
Yeah, started with a strong foundation, so it gives you confidence. We mentioned the baseline characteristic. You presented it at ERS. We had some interesting points, the on and off background antifibrotic therapy, also the geographic spread, which obviously was a bit of a discussion during the phase IIa. Can you walk us through the population you have enrolled and how you wanted to kind of answer some unanswered question from the phase IIa?
Yeah, absolutely. First, in terms of the size of this phase IIb, it is approaching 400 patients, which is actually one of the largest, if not the largest phase II ever run in IPF. The study is a 52-week study, which is the same length as the phase III trials in this space. The study is looking at the primary endpoint, change in lung function FVC at 52 weeks, again, as the registrational endpoint in this disease state. The inclusion criteria are broad, broadly allowing IPF patients to enroll in the trial. We, on lung function, maybe have 5% higher than some of the phase IIIs in a couple of criteria, and that is just to avoid patients who might not be able to stay on the study for the full 12 months, but actually materially then similar inclusion/exclusion criteria as the phase III trials in this space.
Also like the phase III trials in IPF, allowing patients on background therapy and not on background therapy. We enrolled the trial across 14 different countries. Over 100 different clinical sites participated and enrolled patients. These are geographically distributed, almost 30% out of North America, mostly out of the U.S., some population out of South America, about 1/3 , 25% to 1/3 out of Europe, and then Asia Pacific, South Korea, Taiwan, Australia as well. So a really nice broad geographic footprint as well, which we think provides a nice basis to understand what this drug does.
In terms of the types of patients that were ultimately brought in, they look very similar to some of the recently completed phase III trials in IPF. In our corporate deck, we have a comparison to the FIBRONEER study, which was the BI study of nintedanib in phase III, of the TETON studies, which was United Therapeutics' investigation of treprostinil in phase III, and BMS, the ALOFT study that they recently announced was positive as well. What you see here is you have patients who have the same range in terms of time since diagnosis, baseline FVC characteristics, and other kind of lung function features.
We also enrolled a nice mix of patients on standard of care, about 60%, and patients who are not on standard of care therapy, about 40%. In some of these phase III trials, I think it's like up to 35%. We're actually excited to get a little bit more than that in our trial, and we think that'll be a very nice way of understanding how this drug works in monotherapy in a strong way, while also, of course, continuing to have a really nice sizing of patients who are on a background therapy. Ultimately, many clinicians and regulators want to have background therapies enabled in this space, and so we certainly think that this will be a nice basis on which we understand how this drug works with some of the available standard of care too.
Yeah, because having a combination potential is obviously also an edge and a differentiationâ
Yes.
âversus other therapies.
Where that starts really is tolerability, right?
Yeah.
I think that one of the challenges is the currently available therapies, the ability to combine them with each other is very limited. That is because all of them cause GI side effects, so if you are combining two drugs that have the same side effect, that can be very tough for patients to manage, tough for clinicians to manage. So we have a nice opportunity to give overall a well-tolerated drug, but also one that does not have that GI signal.
Yeah, it is about not adding to the burden that the patient already has, right? So, do you have some sort of internal benchmark of what you would expect success to look like? Are you expecting to reproduce the effect you saw in the phase IIa, or could even a lower effect be still significant for the patients?
Yeah. Certainly, we'd love to see that replication. I think what's important to indicate is that's not at all necessary, right? The third of the recently approved drugs, nerandomilast, was actually just approved a little over a year ago, and it's launching very well. Clinicians are really excited to prescribe it, even though the main benefit of this from the prior two therapies is it still causes GI side effects, but maybe better tolerated in the experience of the patients and clinicians, like less GI side effect than the other therapies. That's a very attractive proposition. If you can take even another step forward, for example, and entirely clear that type of a tolerability issue, we think from an efficacy perspective, then a nerandomilast-like efficacy, which is about 65 ml, 70 ml in lung function at 52 weeks, is the starting point.
We think that would be a very attractive therapy. Certainly, if you're able to show even more effect, I think that the therapy becomes all the more attractive from there. I would say that's particularly in the context of something like buloxibutid, because it's shown to be well tolerated in our clinical development to date. It's easy to take. It's an oral small molecule that you take twice daily. I think that really positions us well, either as a monotherapy or ultimately then to be able to combine it with some of these other therapies that already are on the market or future therapies as well.
You mentioned BMS, but we've seen data, not data, but positive outcomes for BMS, for Endeavor, and we will see more when we have the actual numbers, right? What's your take on this development? Do you think it actually raises the bar that you were just mentioning, or too early to say without the numbers?
I think that we'll have to see the numbers, but I think that the bar may be raised now in terms of a requirement for better-tolerated therapies, right? If patients have options, I think that what we've heard from them and from clinicians is then the preference towards the better-tolerated approaches, candidly, even if you have to sacrifice efficacy in some cases, i.e., there's clearly a hierarchy of need. I think because of this patient population, because of the nature of the disease, because of the comorbidities, easier-to-take therapies are going to be very, very attractive.
I think that despite that this is such a fatal disease, I think poorly tolerated therapies might have a challenging time, even if they show good efficacy. I think it'll be very interesting in that light to kind of see some of these, right, recently approved drugs. And some of them do look like they might have the promise to be well tolerated. Candidly, I think that that's then a great opportunity for a drug like buloxibutid. We've observed it also to be well tolerated in development to date, to then combine with some of these newer therapies that might also be easy to take.
Right. Do you think there is Because it's always a question with combination. If you combine a new drug with a generic in terms of pricing, you're still within the acceptable range. But combining newer therapies, then you get a premium on those drugs, and it can cost a lot. From a regulatory perspective, do you think that there's room to get to that higher combined pricing because the need is so great?
Exactly. I think that, right, if we think about this disease as actually being worse than most cancers in terms of prognosis, I think that if you actually can show that your drugs have benefit, I think that it would be very difficult to think that you would not then allow them, right, in places in particular like the U.S. So we think that is something where, of course, you're going to have to have the right drug and the right evidence, but we do think that's possible.
Okay. You said you'll get the results, like mid-2027. What's next? Assuming you have a positive result, you're on to a phase III. What sort of sequence, timeline, what preparation can you do now until you get the results to get the rest of the development on track?
Yeah, absolutely. We are not waiting for the phase IIb results to start our phase III preparations. In fact, we recently completed the first drug substance manufacturing round for phase III drug supply. That is certainly work that has been well underway. We have had regulatory action, including recently with the FDA, on a number of aspects that would support the phase III development as well, and certainly then actively thinking about the design of the phase III, although it would be materially like the phase IIb .
I think that is one of the benefits of our phase IIb , it will really guide us to a nice phase III design. I think we will know what we are aiming for in terms of effect size and other features. Also, of course, even thinking about the operational features like key vendor selection, site selection. All of this type of activity is going to proceed ahead of the phase IIb so that really we can move as quickly as possible after that readout into phase III development.
Should we think, with details being fine-tuned at some point, that the phase III will be largely a confirmation of what you saw on the phase IIb ? If you have a positive phase IIb , then your confidence in the phase III is materially higher than the step you maybe took from phase IIa to phase IIb.
Absolutely, yes. I think that that is also evident when you kind of take our phase IIb and compare it to the other phase IIIs that have previously been conducted in this space, yeah.
Moving away, you have also earlier compounds. Is there anything worth sharing here, or would you say that your focus is 100% advancing in IPF and then just building some earlier stage for the next steps?
Yeah. We're certainly 100% on IPF, and then another 10% on top of that,â
110%
âreally thinking about the potential of this mechanism of action broadly in fibrotic and inflammatory conditions. This axis that we're targeting is the other side of what ACE inhibitors and ARBs do, so losartan and the sartan class. Those drugs have certainly been both safe and well-tolerated broadly and effective across a range of indications, and we likewise think that agonizing the AT2, just like blocking the AT1, can be a very useful way to go after a number of diseases. There are active efforts preclinically in development of follow-on compounds and active thinking for follow-on compounds, and also for buloxibutid about other indication spaces that we could enter over time as well. Stay tuned for that.
Yeah. We'll keep our eyes on IPF for the moment, but look forward to the rest. In terms of partnerships, you have your partner in Japan. How are you thinking about where you want to retain rights, when would be a good time to partner, if you could go alone, being a sort of concentrated disease?
Yeah, absolutely. We're very pleased in 2024 to enter into a regional partnership with Nippon Shinyaku, so license them rights to buloxibutid in Japan. It's a really nice deal from a financials perspective. We get royalties into the low 20s on sales of buloxibutid in Japan, and Japan's an excellent market for IPF, both from a commercial perspective and also from a clinical development perspective, and that was one of the motivators as well. Nippon Shinyaku is a leader in the pulmonary space.
They've actually developed some of the leading compounds for pulmonary hypertension, so they know the clinicians, KOL community in Japan, and they know how to execute pulmonary clinical development there. Certainly, the anticipation is for them to then play a key role in our global phase III in terms of bringing Japanese patients into the trial in a really high-quality way, and so we're really excited about that aspect. Of course, they're already participating with us both operationally and financially in terms of the phase III CMC aspects that we're working on, so the partnership with them has really been quite excellent.
In terms of future partnerships, I think from here, we're excited to do the Japanese partnership, but then we'd like to kind of see what the phase IIb data look like and think a little bit about how we want to position things moving forward before we entertain others. Certainly, I think one of our objectives then is to kind of see about commercializing this therapy in the U.S., but certainly other geographies could be useful to partner in as well.
Yeah, a region like China, it's very hard to go on your own if you don't have a partnership.
Exactly, yes. China is a very interesting geography. The incidence of IPF there is actually significantly higher on a per capita basis vis-Ă -vis places like the U.S. and Europe, so it's a high unmet need in China. Of course, there's then a significant patient population both in terms of a commercial market as well as potentially a clinical development geography as well.
Okay, so we'll wait until the result to get more color on that. Your current funding, it gets you obviously through the readout. How far can you go into the development of buloxibutid with your current runway, excluding any milestone you could get, obviously?
Yeah, absolutely. Certainly, we're really happy to be supported by a group of outstanding investors and shareholders who've been very supportive to the company, and we really appreciate that. The capital that we've raised is sufficient for us to achieve the phase IIb readout and have runway thereafter. Certainly, we would need to raise additional capital in order to then subsequently execute the phase III. I think there are a lot of different ways that we can look at doing that, and that's something that we actively think about as well. Then certainly, one thing that we think is that the value proposition will be very clear and attractive given the nature of the phase IIb to allow folks to support us for phase III development as well.
Yeah, we know in biotech, if you have great phase IIb result, then capital is easier to follow than in any other cases. That's great. Maybe just to recap everything, I think we've covered most of the topics. Can you give us a brief overview of what we can expect in the next 12- 18 monthsâ
Yeah.
âfrom you guys?
Yeah. I would say both from us as well as the field in general. I think that what's becoming more and more clear to folks with the launch of one new therapy for IPF after almost a decade or more than a decade without one is that the nature of the unmet need, the nature of the commercial opportunity is quite significant. I think that that's a realization that'll continue to become apparent over time, as we also then will see a few other interesting readouts in the landscape and more data in the landscape over the next 12 months, including, you mentioned BMS and Endeavor, who had some clinical readouts.
I think that'll be interesting to see as well and sort of firm up the landscape ahead of Vicore, so that we understand how to kind of the details around our phase III development as well. So we're really excited for that, and of course, it's not so long now until we get our readout over the summer, so we're certainly looking forward to that as well.
We're all so excited for you. Thank you so much for taking the time.
Of course, I am always happy to. Thank you for having me. Thank you, Clémence.
Thank you.